|
JAK2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.06169534169953E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.20229953665319E-10 |
| Normal-vs-Stage2 |
5.5596638404154E-12 |
| Normal-vs-Stage3 |
1.07047704034358E-12 |
| Normal-vs-Stage4 |
1.39600553339392E-11 |
| Stage1-vs-Stage2 |
2.263700E-02 |
| Stage1-vs-Stage3 |
2.626200E-01 |
| Stage1-vs-Stage4 |
2.307500E-02 |
| Stage2-vs-Stage3 |
2.946200E-01 |
| Stage2-vs-Stage4 |
7.584000E-01 |
| Stage3-vs-Stage4 |
2.312000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.02659991618737E-10 |
| Normal-vs-AfricanAmerican |
1.42349998455416E-09 |
| Normal-vs-Asian |
1.37409994493964E-09 |
| Caucasian-vs-AfricanAmerican |
4.080400E-01 |
| Caucasian-vs-Asian |
6.806400E-01 |
| AfricanAmerican-vs-Asian |
7.712600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.05090389115981E-11 |
| Normal-vs-Female |
6.01749761131032E-11 |
| Male-vs-Female |
3.402200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.02182715014487E-12 |
| Normal-vs-Age(41-60Yrs) |
7.75834951838306E-12 |
| Normal-vs-Age(61-80Yrs) |
3.11073389269723E-12 |
| Normal-vs-Age(81-100Yrs) |
1.449810E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.221790E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.271000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.086600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.747600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.515800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.569400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.985800E-01 |
| Classical-VS-Follicular |
3.778500E-03 |
| Classical-VS-Other |
6.433700E-02 |
| Classical-VS-Normal |
9.08090047602172E-10 |
| Tall-VS-Follicular |
2.089600E-01 |
| Tall-VS-Other |
1.681210E-01 |
| Tall-VS-Normal |
2.75469999999611E-06 |
| Follicular-VS-Other |
3.194400E-01 |
| Follicular-VS-Normal |
1.43507428163048E-12 |
| Other-VS-Normal |
1.036710E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.00800479074792E-11 |
| Normal-vs-N1 |
5.24691401437849E-12 |
| N0-vs-N1 |
3.443200E-01 |
|
|
